Clinical trials: Treatment Resistant Major Depression
Treatment Resistant Depression, Generalized Anxiety Disorder
An Open Label Study of Clinical Utility and Patient Outcomes of the Genecept Assay
Genomind has developed and introduced a battery of genetic tests, the Genecept Assay, which clinicians can administer to patients using a simple saliva sample technique. The present study proposes to enroll 1.
- Trial name
- COM-1 (NCT01507155)
- Testing
- Genecept Assay
- Where
- United States
- Volunteers
- 685 people
- Sponsor
- Genomind, LLC
Major Depressive Disorder, Depression
Buprenorphine Used With Treatment Resistant Depression in Older Adults
The investigators are conducting a research study to learn about the safety and benefit of using a medication called buprenorphine for patients with difficult to treat depression.
- Trial name
- IRLGreyB (NCT02181231)
- Testing
- venlafaxine XR, buprenorphine
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Washington University School of Medicine
Depression
A Study of Infliximab for Treatment Resistant Major Depression
Major depression is increasingly recognized to be a chronic and highly recurrent condition, which results in significantly increased health problems.
- Trial name
- Infliximab (NCT00463580)
- Testing
- Infliximab
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Emory University
Major Depressive Disorder, Treatment-Resistant Depression
Antidepressant Effects of TS-161 in Treatment-Resistant Depression
Background: Major depressive disorder (MDD) is a common, chronic mental illness. It can take weeks to months for antidepressants to work. Researchers want to test a new drug that might act more rapidly.
- Conditions
- Major Depressive Disorder, Treatment-Resistant Depression, Depression
- Trial name
- NCT04821271
- Testing
- TS-161
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- National Institute of Mental Health (NIMH)
Treatment Resistant Depression
KET-RO Plus RO DBT for Treatment Resistant Depression
This pilot study will assess the safety and feasibility of intravenous (IV) ketamine combined with RO DBT in young adults with Treatment-Resistant Depression (TRD).
- Trial name
- KET-RO (NCT06138691)
- Testing
- Ketamine Infusion plus RO DBT
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Washington University School of Medicine
Major Depressive Disorder
Deep Brain Stimulation for Treatment Resistant Depression
The purpose of this study is to test the safety, efficacy and mechanism of action of subgenual cingulate (Cg25) deep brain stimulation (DBS) for major depression in patients who have not responded to prior antidepressant…
- Trial name
- NCT00367003
- Testing
- Deep Brain Stimulation
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- Emory University
Treatment Resistant Depression
Stanford Accelerated Intelligent Neuromodulation Therapy for Treatment-Resistant Depression: OL Cohort
This study evaluates an accelerated schedule of theta-burst stimulation using a transcranial magnetic stimulation device for treatment-resistant depression.
- Trial name
- SAINT-TRD (NCT03240692)
- Testing
- Accelerated theta-burst stimulation treatment
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Stanford University
Depression, Mood Disorders
Rapid Antidepressant Effects of Ketamine in Major Depression
Depressive disorders may be severe, chronic and often life-threatening illnesses. Impairment in physical and social functioning resulting from depression can be just as severe as other chronic medical illnesses.
- Conditions
- Depression, Mood Disorders, Major Depresssion
- Trial name
- NCT00088699
- Testing
- Ketamine
- Where
- United States
- Volunteers
- 67 people, healthy volunteers welcome
- Sponsor
- National Institute of Mental Health (NIMH)
Major Depressive Disorder
Aripiprazole Augmentation of SSRI Therapy in Treatment Refractory Depression
Our target population will have been adequately treated with one of three selective serotonin reuptake inhibitors (SSRIs; escitalopram, citalopram, or sertraline) for at least 8-12 weeks and continue to experience symptoms of…
- Trial name
- NCT00608543
- Testing
- Aripiprazole
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- University of Texas Southwestern Medical Center
Major Depressive Disorder
Vagal Nerve Stimulation for Treatment Resistant Major Depression
The purpose of this study is to 1) explore whether vagal nerve stimulation (nVNS) using a hand- held non-invasive device (gammaCore™) works to treat depression and 2) to confirm gammaCore™'s safety profile.
- Trial name
- NCT04990687
- Testing
- gammaCore™
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- University of Alabama at Birmingham
Depressive Disorder, Major
A Long-Term Extension Study for Participants With Treatment-resistant Major Depressive Disorder Who Are Continuing Esketamine Nasal Spray Treatment
The primary purpose of this study is to assess the long-term safety and tolerability of esketamine nasal spray in combination with a selective serotonin reuptake inhibitor/serotonin-norepinephrine reuptake inhibitor (SSRI/SNRI)…
- Trial name
- ESCAPE-LTE (NCT04829318)
- Testing
- Esketamine, SSRI/SNRI
- Where
- 59 sites in Argentina, Belgium and 12 more
- Volunteers
- 183 people
- Sponsor
- Janssen-Cilag Ltd.
Treatment Resistant Depression
Double-Blind, Placebo-Controlled Trial of Ketamine Therapy in Treatment-Resistant Depression (TRD)
This study is looking at the efficacy, durability, safety, and tolerability of multiple single doses of Ketamine vs. active placebo for treating patients with treatment resistant depression who are taking an antidepressant that…
- Trial name
- NCT01920555
- Testing
- Ketamine
- Where
- 6 sites in United States
- Volunteers
- 99 people
- Sponsor
- Massachusetts General Hospital
Major Depressive Disorder
Ketamine Versus Placebo for Treatment Resistant Major Depressive Disorder
Ketamine infusions resulted in an acute reduction in global depression scores and in severity of suicidal ideation. The investigators therefore plan to investigate the feasibility and efficacy of repeated intravenous…
- Trial name
- NCT01667926
- Testing
- Ketamine
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- Massachusetts General Hospital
Depression
Efficacy and Tolerability of Riluzole in Treatment Resistant Depression
This study aims to examine the antidepressant efficacy of riluzole, employing a randomized, double-blind, placebo-controlled, adjunctive trial in treatment-resistant major depressive disorder (TRD).
- Trial name
- NCT01204918
- Testing
- Riluzole
- Where
- 3 sites in United States
- Volunteers
- 104 people
- Sponsor
- Yale University
Treatment Resistant Depression, Major Depressive Disorder
Open-Label Safety Study of AXS-05 in Subjects With TRD (EVOLVE)
This study is a multi-center, open-label trial to evaluate the long-term safety and efficacy of AXS-05 in subjects with major depressive disorder with prior treatment failures
- Trial name
- NCT04634669
- Testing
- AXS-05 (dextromethorphan-bupropion)
- Where
- 20 sites in United States
- Volunteers
- 181 people
- Sponsor
- Axsome Therapeutics, Inc.
Major Depressive Disorder
Cysteamine Therapy for Major Depressive Disorder
The purpose of this study is to determine whether cysteamine bitartrate, an FDA-approved drug for a non-psychiatric condition, is safe and effective for the treatment of major depression.
- Trial name
- NCT00715559
- Testing
- cysteamine bitartrate
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Depressive Disorder, Major
A Long-term Comparison of Esketamine Nasal Spray Versus Quetiapine Extended Release, Both in Combination With a Selective Serotonin Reuptake Inhibitor/Serotonin-Norepinephrine Reuptake Inhibitor, in Participants With Treatment Resistant Major Depressive Disorder
The primary purpose of this study is to evaluate the efficacy of flexibly dosed esketamine nasal spray compared with quetiapine extended-release (XR), both in combination with a continuing selective serotonin reuptake…
- Trial name
- ESCAPE-TRD (NCT04338321)
- Testing
- Esketamine 28 mg, Esketamine 56 mg, Esketamine 84 mg
- Where
- 171 sites in Argentina, Austria and 22 more
- Volunteers
- 676 people
- Sponsor
- Janssen-Cilag International NV
Treatment Resistant Depression, Major Depressive Disorder
The UTHealth Ketamine Project
The primary objective of this study is to determine the effectiveness of serial infusions of intravenous (IV) ketamine in adults with treatment resistant depression (TRD).
- Conditions
- Treatment Resistant Depression, Major Depressive Disorder, Bipolar Disorder
- Trial name
- NCT02882711
- Testing
- Ketamine
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- The University of Texas Health Science Center, Houston
Suicidal Ideation
Ketamine For Suicidal Ideation
This study will examine the effects of Intravenous (IV) ketamine both in an outpatient population and with subjects on the inpatient unit with suicidal ideation (SI).
- Trial name
- NCT01507181
- Testing
- Ketamine, Midazolam
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- James Murrough
Major Depressive Disorder
Rapid Antidepressant Effects of Leucine
This randomized double-blind placebo-controlled crossover study seeks to evaluate the antidepressant effect of L-leucine, an essential amino acid, in patients with Major Depressive Disorder (MDD).
- Trial name
- NCT03079297
- Testing
- L-Leucine, Maltodextrin
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- University of Texas Southwestern Medical Center